Clinical Trial

SIGNATURE Study : DCB (Legflow) vs POBA in Fempop Arteries

Study acronym: SIGNATURE
Active, Not Recruiting
View on ClinicalTrials.gov →
Summary
The aim of this study is to demonstrate the superiority in safety and efficacy of the Legflow DCB vs standard uncoated POBA in a randomized controlled (RCT) for treatment of patients with symptomatic peripheral artery disease (PAD) due to stenosis, restenosis or occlusion of the femoral and/or popliteal arteries.
Protocol Amendment History 5 amendments
This ClinicalTrials.gov record has been amended 5 times since 2021-07-20; most recent amendment 2026-03-17.
Status change: Recruiting → Active, Not Recruiting 2026-03-17
Status change: Not Yet Recruiting → Recruiting 2022-08-10
Trial Details
NCT Number NCT04971772
Lead Sponsor Cardionovum GmbH
Collaborators: FCRE (Foundation for Cardiovascular Research and Education)
Conditions Peripheral Arterial Disease, Superficial Femoral Artery Stenosis, Angiopathy, Peripheral
Enrollment 150 participants
Start Date 2022-06-08
Primary Completion 2026-12 (estimated)
Study Completion 2028-01 (estimated)
Updated on ClinicalTrials.gov 2026-03-19